FDAta by datagemba
Home
Contact
About
Account
Login
Signup
Toggle theme
Light
Dark
Auto
Citations within the context of their regulations
Review the enforcement history for every citation given out with the Biologics sector.
Chapter I: Additional Standards for Miscellaneous Products
Chapter I: None
21 CFR 680.1 - Allergenic Products.
21 CFR 680.1(b) - (b) Source materials —
21 CFR 680.1(b)(2) - (2) Molds.
21 CFR 680.1(b)(2)(iii) - (iii) Mold manufacturers shall maintain written standard operating procedures, developed by a qua...
Enforcement history
Companies cited for this
Warning Letters
Part 600: Biological Products: General
Subpart B: Establishment Standards
21 CFR 600.10 - Personnel.
21 CFR 600.10(b) - (b) Personnel. Personnel shall have capabilities commensurate with their assigned functions, a t...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.12 - Records.
21 CFR 600.12(a) - (a) Maintenance of records. Records shall be made, concurrently with the performance, of each st...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.12(c) - (c) Records of sterilization of equipment and supplies. Records relating to the mode of steriliz...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.12(b) - (b) Records retention —
21 CFR 600.12(b)(1) - (1) General. Records shall be retained for such interval beyond the expiration date as is necess...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.12(b)(2) - (2) Records of recall. Complete records shall be maintained pertaining to the recall from distri...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.14 - Reporting of biological product deviations by licensed manufacturers.
21 CFR 600.14(c) - (c) When do I report under this section? You should report a biological product deviation as soo...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.14(a) - (a) Who must report under this section?
21 CFR 600.14(a)(1) - (1) You, the manufacturer who holds the biological product license and who had control over the p...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.15 - Temperatures during shipment.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.11 - Physical establishment, equipment, animals, and care.
21 CFR 600.11(a) - (a) Work areas. All rooms and work areas where products are manufactured or stored shall be kept...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.11(b) - (b) Equipment. Apparatus for sterilizing equipment and the method of operation shall be such as ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.11(h) - (h) Containers and closures. All final containers and closures shall be made of material that wi...
Enforcement history
Companies cited for this
Warning Letters
Subpart D: Reporting of Adverse Experiences
21 CFR 600.80 - Postmarketing reporting of adverse experiences.
21 CFR 600.80(b) - (b) Review of adverse experiences. Any person having a biologics license under § 601.20 of this ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c) - (c) Reporting requirements
21 CFR 600.80(c) - (c) Reporting requirements
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c)(1) - (1)
21 CFR 600.80(c)(1)(i) - (i) Postmarketing 15-day “Alert reports”. The applicant must report each adverse experience that...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c)(1)(ii) - (ii) Postmarketing 15-day “Alert reports”—followup. The applicant must promptly investigate all ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c)(1)(iii) - (iii) Submission of reports. The requirements of paragraphs (c)(1)(i) and (c)(1)(ii) of this sec...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c)(2) - (2) Periodic adverse experience reports.
21 CFR 600.80(c)(2)(i) - (i) The applicant must report each adverse experience not reported under paragraph (c)(1)(i) of t...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.80(c)(2)(ii) - (ii) Each periodic report is required to contain:
Enforcement history
Companies cited for this
Warning Letters
21 CFR 600.81 - Distribution reports.
Enforcement history
Companies cited for this
Warning Letters
Part 601: Licensing
Subpart C: Biologics Licensing
21 CFR 601.12 - Changes to an approved application.
21 CFR 601.12(c) - (c) Changes requiring supplement submission at least 30 days prior to distribution of the product...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 601.12(b) - (b) Changes requiring supplement submission and approval prior to distribution of the product mad...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 601.12(d) - (d) Changes to be described in an annual report (minor changes).
Enforcement history
Companies cited for this
Warning Letters
21 CFR 601.12(f) - (f) Labeling changes.
21 CFR 601.12(f)(1) - (1) Labeling changes requiring supplement submission—FDA approval must be obtained before distrib...
Enforcement history
Companies cited for this
Warning Letters
Part 606: Current Good Manufacturing Practice for Blood and Blood Components
Subpart B: Organization and Personnel
21 CFR 606.20 - Personnel.
21 CFR 606.20(c) - (c) Persons whose presence can adversely affect the safety and purity of the products shall be ex...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.20(b) - (b) The personnel responsible for the collection, processing, compatibility testing, storage or d...
Enforcement history
Companies cited for this
Warning Letters
Subpart C: Plant and Facilities
21 CFR 606.40 - Facilities.
21 CFR 606.40(c) - (c) Provide adequate, clean, and convenient handwashing facilities for personnel, and adequate, c...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(b) - (b) Provide adequate lighting, ventilation and screening of open windows and doors.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40 - Facilities.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(d) - (d) Provide for safe and sanitary disposal for the following:
21 CFR 606.40(d)(2) - (2) Blood and blood components not suitable for use or distribution.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a) - (a) Provide adequate space for the following when applicable:
21 CFR 606.40(a)(1) - (1) Private and accurate examinations of individuals to determine their eligibility as blood dono...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a)(2) - (2) The withdrawal of blood from donors with minimal risk of contamination, or exposure to activi...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a)(3) - (3) The storage of blood or blood components pending completion of tests.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a)(6) - (6) The quarantine storage, handling and disposition of products and reagents not suitable for us...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a)(7) - (7) The orderly collection, processing, compatibility testing, storage and distribution of blood ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.40(a)(9) - (9) The orderly conduction of all packaging, labeling and other finishing operations.
Enforcement history
Companies cited for this
Warning Letters
Subpart D: Equipment
21 CFR 606.65 - Supplies and reagents.
21 CFR 606.65(c) - (c) Representative samples of each lot of the following reagents or solutions shall be tested on ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.65(e) - (e) Supplies and reagents shall be used in a manner consistent with instructions provided by the ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.65 - Supplies and reagents.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.60 - Equipment.
21 CFR 606.60(b) - (b) Equipment that shall be observed, standardized and calibrated with at least the following fre...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.60(a) - (a) Equipment used in the collection, processing, compatibility testing, storage and distribution...
Enforcement history
Companies cited for this
Warning Letters
Subpart F: Production and Process Controls
21 CFR 606.110 - Plateletpheresis, leukapheresis, and plasmapheresis.
21 CFR 606.110(b) - (b) Plasmapheresis of donors who do not meet the donor requirements of §§ 630.10, 630.15, 640.64 ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.110(a) - (a) The use of plateletpheresis and leukapheresis procedures to obtain a product for a specific r...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100 - Standard operating procedures.
21 CFR 606.100(c) - (c) All records pertinent to the lot or unit maintained pursuant to these regulations shall be re...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(a) - (a) In all instances, except clinical investigations, standard operating procedures shall comply ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b) - (b) Establishments must establish, maintain, and follow written standard operating procedures for...
21 CFR 606.100(b) - (b) Establishments must establish, maintain, and follow written standard operating procedures for...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(1) - (1) Criteria used to determine donor eligibility, including acceptable medical history criteria.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(10) - (10) Storage temperatures and methods of controlling storage temperatures for all blood products ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(12) - (12) Criteria for determining whether returned blood is suitable for reissue.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(13) - (13) Procedures used for relating a unit of blood or blood component from the donor to its final ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(14) - (14) Quality control procedures for supplies and reagents employed in blood collection, processin...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(15) - (15) Schedules and procedures for equipment maintenance and calibration.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(16) - (16) Labeling procedures, including safeguards to avoid labeling mixups.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(18) - (18) Procedures for preparing recovered plasma, if performed, including details of separation, po...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(19) - (19) Procedures under §§ 610.46 and 610.47 of this chapter:
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(2) - (2) Methods of performing donor qualifying tests and measurements, including minimum and maximum ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(20) - (20) Procedures for donor deferral as prescribed in § 610.41 of this chapter.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(21) - (21) Procedures for donor notification and notification of the referring physician of an autologo...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(22) - (22) Procedures to control the risks of bacterial contamination of platelets, including all steps...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(3) - (3) Solutions and methods used to prepare the site of phlebotomy to give maximum assurance of a s...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(4) - (4) Method of accurately relating the product(s) to the donor.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(5) - (5) Blood collection procedure, including in-process precautions taken to measure accurately the ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(6) - (6) Methods of component preparation, including any time restrictions for specific steps in proce...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(7) - (7) All tests and repeat tests performed on blood and blood components during manufacturing.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(8) - (8) Pretransfusion testing, where applicable, including precautions to be taken to identify accur...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.100(b)(9) - (9) Procedures for investigating adverse donor and recipient reactions.
Enforcement history
Companies cited for this
Warning Letters
Subpart G: Additional Labeling Standards for Blood and Blood Components
21 CFR 606.122 - Circular of information.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121 - Container label.
21 CFR 606.121(h) - (h) The following additional information must appear on the label for blood and blood components ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(b) - (b) The label provided by the collecting facility and the initial processing facility must not be...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(f) - (f) Blood and blood components determined to be unsuitable for transfusion must be prominently la...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c) - (c) The container label must include the following information, as well as other specialized info...
21 CFR 606.121(c)(1) - (1) The proper name of the product in a prominent position, with any appropriate modifiers and at...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(11) - (11) If the product is intended for further manufacturing use, a statement listing the results of...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(12) - (12) The blood and blood components must be labeled in accordance with § 610.40 of this chapter, ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(13) - (13) The container label of blood or blood components intended for transfusion must bear encoded ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(2) - (2) The name, address, unique facility identifier, and, if a licensed product, the license number...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(7) - (7) The recommended storage temperature (in degrees Celsius).
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(8) - (8) If the product is intended for transfusion, the statements:
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(9) - (9) If the product is intended for transfusion or as is otherwise appropriate, the ABO group and ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(4) - (4)
21 CFR 606.121(c)(4)(i) - (i) The expiration date, including the day, month, and year, and, if the dating period for the pr...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(c)(4)(ii) - (ii) If Source Plasma intended for manufacturing into noninjectable products is pooled, the expir...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(e) - (e) Container label requirements for particular products or groups of products
21 CFR 606.121(e) - (e) Container label requirements for particular products or groups of products
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.121(e)(5) - (5) Source Plasma labels must include the following information:
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.120 - Labeling, general requirements.
21 CFR 606.120(a) - (a) Labeling operations shall be separated physically or spatially from other operations in a man...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.120(b) - (b) The labeling operation shall include the following labeling controls:
21 CFR 606.120(b)(2) - (2) Each type of label representing different products shall be stored and maintained in a manner...
Enforcement history
Companies cited for this
Warning Letters
Subpart H: Laboratory Controls
21 CFR 606.140 - Laboratory controls.
21 CFR 606.140(b) - (b) Adequate provisions for monitoring the reliability, accuracy, precision and performance of la...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.140(a) - (a) The establishment of scientifically sound and appropriate specifications, standards and test ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.140(c) - (c) Adequate identification and handling of all test samples so that they are accurately related ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.151 - Compatibility testing.
21 CFR 606.151(d) - (d) A provision that, if the unit of donor's blood has not been screened by a method that will de...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.151(e) - (e) Procedures to expedite transfusion in life-threatening emergencies. Records of all such incid...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.151(a) - (a) A method of collecting and identifying the blood samples of recipients to ensure positive ide...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.145 - Control of bacterial contamination of platelets.
21 CFR 606.145(d) - (d) In the event that a contaminating organism is identified under paragraph (b) or (c) of this s...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.145(b) - (b) In the event that a blood collection establishment identifies platelets as bacterially contam...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.145(a) - (a) Blood collection establishments and transfusion services must assure that the risk of bacteri...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.145(c) - (c) In the event that a transfusion service identifies platelets as bacterially contaminated, the...
Enforcement history
Companies cited for this
Warning Letters
Subpart I: Records and Reports
21 CFR 606.165 - Distribution and receipt; procedures and records.
21 CFR 606.165(c) - (c) Receipt records shall contain the name and address of the collecting facility, date received,...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.165(b) - (b) Distribution records shall contain information to readily facilitate the identification of th...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.165(a) - (a) Distribution and receipt procedures shall include a system by which the distribution or recei...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.171 - Reporting of product deviations by licensed manufacturers, unlicensed registered blood establishm...
21 CFR 606.171(a) - (a) Who must report under this section? You, a licensed manufacturer of blood and blood componen...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.171 - Reporting of product deviations by licensed manufacturers, unlicensed registered blood establishm...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.170 - Adverse reaction file.
21 CFR 606.170(a) - (a) Records shall be maintained of any reports of complaints of adverse reactions regarding each ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.170(b) - (b) When a complication of blood collection or transfusion is confirmed to be fatal, the Director...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160 - Records.
21 CFR 606.160(c) - (c) A donor number shall be assigned to each accepted donor, which relates the unit of blood coll...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(d) - (d) Records shall be retained for such interval beyond the expiration date for the blood or blood...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(a) - (a)
21 CFR 606.160(a)(1) - (1) Records shall be maintained concurrently with the performance of each significant step in the...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(a)(2) - (2) Appropriate records shall be available from which to determine lot numbers of supplies and re...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(e) - (e) Records of deferred donors.
21 CFR 606.160(e)(1) - (1) Establishments must maintain at each location a record of all donors found to be ineligible o...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(e)(2) - (2) Establishments must maintain at all locations operating under the same license or under commo...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(b) - (b) Records shall be maintained that include, but are not limited to, the following when applicab...
21 CFR 606.160(b) - (b) Records shall be maintained that include, but are not limited to, the following when applicab...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 606.160(b)(6) - (6) Transfusion reaction reports and complaints, including records of investigations and followup...
Enforcement history
Companies cited for this
Warning Letters
Part 610: General Biological Products Standards
Subpart A: Release Requirements
21 CFR 610.1 - Tests prior to release required for each lot.
Enforcement history
Companies cited for this
Warning Letters
Subpart B: General Provisions
21 CFR 610.18 - Cultures.
21 CFR 610.18(b) - (b) Identity and verification. Each culture shall be clearly identified as to source strain. A c...
Enforcement history
Companies cited for this
Warning Letters
Subpart E: Testing Requirements for Relevant Transfusion-Transmitted Infections
21 CFR 610.46 - Human immunodeficiency virus (HIV) “lookback” requirements.
21 CFR 610.46(a) - (a) If you are an establishment that collects Whole Blood or blood components, including Source P...
21 CFR 610.46(a) - (a) If you are an establishment that collects Whole Blood or blood components, including Source P...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.46(a)(1) - (1) Within 3 calendar days after a donor tests reactive for evidence of human immunodeficiency vi...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.46(a)(2) - (2) You must perform further testing for HIV as required under § 610.40(e) of this chapter on the...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.46(b) - (b) If you are a consignee of Whole Blood or blood components, including Source Plasma and Source...
21 CFR 610.46(b) - (b) If you are a consignee of Whole Blood or blood components, including Source Plasma and Source...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.46(b)(3) - (3) When further testing for HIV is positive or when the screening test is reactive and further t...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.41 - Donor deferral.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47 - Hepatitis C virus (HCV) “lookback” requirements.
21 CFR 610.47 - Hepatitis C virus (HCV) “lookback” requirements.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47(a) - (a) If you are an establishment that collects Whole Blood or blood components, including Source P...
21 CFR 610.47(a) - (a) If you are an establishment that collects Whole Blood or blood components, including Source P...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47(a)(1) - (1) Within 3 calendar days after a donor tests reactive for evidence of hepatitis C virus (HCV) i...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47(a)(3) - (3) You must notify consignees of the results of further testing for HCV, or the results of the r...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47(b) - (b) If you are a consignee of Whole Blood or blood components, including Source Plasma or Source ...
21 CFR 610.47(b) - (b) If you are a consignee of Whole Blood or blood components, including Source Plasma or Source ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.47(b)(3) - (3) When the further testing for HCV is positive or when the screening test is reactive and furth...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40 - Test requirements.
21 CFR 610.40(f) - (f) Testing responsibility. Required testing under this section, must be performed by a laborato...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(b) - (b) Testing using one or more licensed, approved, or cleared screening tests. To perform testing...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(e) - (e) Further testing. You must further test each donation, including autologous donations, found ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(d) - (d) Autologous donations. You, an establishment that collects human blood or blood components fr...
21 CFR 610.40(d)(4) - (4) Each autologous donation must be labeled as required under § 606.121 of this chapter and with...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(h) - (h) Restrictions on shipment or use —
21 CFR 610.40(h) - (h) Restrictions on shipment or use —
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(h)(2) - (2) Exceptions.
21 CFR 610.40(h)(2)(ii) - (ii) You must not ship or use human blood or blood components that have a reactive screening test...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(c) - (c) Exceptions to testing for dedicated donations, medical devices, and samples. —
21 CFR 610.40(c)(2) - (2) Medical device.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(a) - (a) Human blood and blood components
21 CFR 610.40(a) - (a) Human blood and blood components
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.40(a)(2) - (2) Test each donation for evidence of infection due to the relevant transfusion-transmitted infe...
Enforcement history
Companies cited for this
Warning Letters
Subpart F: Dating Period Limitations
21 CFR 610.53 - Dating periods for Whole Blood and blood components.
21 CFR 610.53(b) - (b) Table of dating periods. In using the table in this paragraph, when a product in column A is...
Enforcement history
Companies cited for this
Warning Letters
Subpart G: Labeling Standards
21 CFR 610.60 - Container label.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 610.63 - Divided manufacturing responsibility to be shown.
Enforcement history
Companies cited for this
Warning Letters
Part 630: Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use
Subpart B: Donor Eligibility Requirements
21 CFR 630.5 - Medical supervision.
21 CFR 630.5(d) - (d) Must rapid emergency medical services be available ? Establishments that collect blood or blo...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.5(c) - (c) Which activities related to the collection of Source Plasma and plasma collected by plasmaphe...
21 CFR 630.5(c)(1) - (1) Donor eligibility and blood component collection activities.
21 CFR 630.5(c)(1)(i) - (i) The responsible physician may delegate to a physician substitute or other trained person any ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10 - General donor eligibility requirements.
21 CFR 630.10(b) - (b) What educational material must you provide to the donor before determining eligibility ? You ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(c) - (c) When must you determine the eligibility of a donor ? You must determine donor eligibility on ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(h) - (h) What must you do when a donor is not eligible ? You must not collect blood or blood component...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(f) - (f) How do you perform a physical assessment of the donor ? You must determine on the day of dona...
21 CFR 630.10(f)(4) - (4) Pulse. The donor's pulse must be regular and between 50 and 100 beats per minute. A donor wi...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(f)(3) - (3) Hemoglobin or hematocrit determination
21 CFR 630.10(f)(3) - (3) Hemoglobin or hematocrit determination
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(f)(3)(i) - (i) Allogeneic donors must have a hemoglobin level or hematocrit value that is adequate to assure...
21 CFR 630.10(f)(3)(i)(B) - (B) Male allogeneic donors must have a hemoglobin level that is equal to or greater than 13.0 gra...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(f)(6) - (6) Skin examination.
21 CFR 630.10(f)(6)(i) - (i) The donor's phlebotomy site must be free of infection, inflammation, and lesions; and
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(f)(6)(ii) - (ii) The donor's arms and forearms must be free of punctures and scars indicative of injected dru...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(g) - (g) Are there additional requirements for determining the eligibility of the donor ? You must obt...
21 CFR 630.10(g)(1) - (1) Proof of identity and postal address. You must obtain proof of identity of the donor and a p...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(g)(2) - (2) Donor's acknowledgement
21 CFR 630.10(g)(2) - (2) Donor's acknowledgement
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(g)(2)(ii) - (ii) The donor acknowledgement must not include any exculpatory language through which the donor ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(d) - (d) How must you determine the eligibility of a donor ? You must determine the donor's eligibilit...
21 CFR 630.10(d)(2) - (2) Assure that the interval since the donor's last donation is appropriate;
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(d)(4) - (4) Perform a physical assessment of the donor.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(e) - (e) How do you assess the donor's medical history ? Before collection you must conduct a medical ...
21 CFR 630.10(e) - (e) How do you assess the donor's medical history ? Before collection you must conduct a medical ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(e)(1) - (1) Factors that make the donor ineligible to donate because of an increased risk for, or evidenc...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.10(e)(2) - (2) Other factors that make the donor ineligible to donate. A donor is ineligible to donate when ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30 - Donation suitability requirements.
21 CFR 630.30(b) - (b) What must you do when the donation is not suitable ?
21 CFR 630.30(b)(1) - (1) You must not release the donation for transfusion or further manufacturing use unless it is a...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30(b)(2) - (2) You must defer the donor when a donation is determined to be unsuitable based on the criteria...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30(a) - (a) When is a donation suitable ? A donation is suitable when:
21 CFR 630.30(a) - (a) When is a donation suitable ? A donation is suitable when:
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30(a)(1) - (1) The donor is not currently deferred from donation as determined by review of the records of d...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30(a)(2) - (2) The results in accordance with §§ 630.10 through 630.25 indicate that the donor is in good he...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.30(a)(3) - (3) The results in accordance with § 630.10(e) indicate that the donor is free from risk factors ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15 - Donor eligibility requirements specific to Whole Blood, Red Blood Cells and Plasma collected by a...
21 CFR 630.15(b) - (b) What additional donor eligibility requirements apply when you, an establishment that collects...
21 CFR 630.15(b)(3) - (3) Weight. You must weigh a donor at each donation.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15(b)(6) - (6) Deferral of donors due to red blood cell loss.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15(b)(1) - (1) Medical history and physical examination
21 CFR 630.15(b)(1) - (1) Medical history and physical examination
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15(b)(1)(ii) - (ii) The responsible physician must examine the donor for medical conditions that would place the...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15(b)(2) - (2) What requirements apply to obtaining informed consent ?
21 CFR 630.15(b)(2) - (2) What requirements apply to obtaining informed consent ?
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.15(b)(2)(iii) - (iii) The responsible physician must explain the risks and hazards of the procedure to the donor....
Enforcement history
Companies cited for this
Warning Letters
Subpart C: Donor Notification
21 CFR 630.40 - Requirements for notifying deferred donors.
21 CFR 630.40(c) - (c) Time period for notification. You must make reasonable attempts to notify the donor within 8...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(a) - (a) Notification of donors. You, an establishment that collects blood or blood components, must ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(d) - (d) Autologous donors.
21 CFR 630.40(d)(1) - (1) You also must provide the following information to the referring physician of an autologous d...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(d)(2) - (2) You must make reasonable attempts to notify the autologous donor's referring physician within...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(b) - (b) Content of notification. You must provide the following information to a donor deferred or d...
21 CFR 630.40(b)(1) - (1) That the donor is deferred or determined not to be eligible for donation and the reason for t...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(b)(2) - (2) Where appropriate, the types of donation of blood or blood components that the donor should n...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(b)(3) - (3) Where applicable, the results of tests for evidence of infection due to relevant transfusion-...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 630.40(b)(4) - (4) Where appropriate, information concerning medical followup and counseling.
Enforcement history
Companies cited for this
Warning Letters
Part 640: Additional Standards for Human Blood and Blood Products
Subpart A: Whole Blood
21 CFR 640.2 - General requirements.
21 CFR 640.2(c) - (c) Reissue of blood. Blood that has been removed from storage controlled by a licensed establis...
21 CFR 640.2(c)(3) - (3) The blood has been stored continuously at 1 to 6 °C and shipped between 1 and 10 °C;
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.4 - Collection of the blood.
21 CFR 640.4(h) - (h) Storage. Whole Blood must be placed in storage at a temperature between 1 and 6 °C immediate...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.4(f) - (f) Prevention of contamination of the blood. The skin of the donor at the site of phlebotomy sh...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.4(g) - (g) Samples and segments for laboratory tests. Samples and segments for laboratory tests shall m...
21 CFR 640.4(g)(3) - (3) All containers for all samples shall bear the donor's identification before collecting the sa...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.5 - Testing the blood.
21 CFR 640.5(e) - (e) Inspection. Whole Blood shall be inspected visually during storage and immediately prior to ...
Enforcement history
Companies cited for this
Warning Letters
Subpart B: Red Blood Cells
21 CFR 640.15 - Segments for testing.
21 CFR 640.15(a) - (a) One or more segments shall be provided with each unit of Whole Blood or Red Blood Cells when ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.16 - Processing.
21 CFR 640.16(b) - (b) Sterile system. All surfaces that come in contact with the red cells shall be sterile and py...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.11 - General requirements.
21 CFR 640.11(a) - (a) Storage. Immediately after processing, the Red Blood Cells shall be placed in storage and ma...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.11(b) - (b) Inspection. The product shall be inspected immediately after separation of the plasma, perio...
Enforcement history
Companies cited for this
Warning Letters
Subpart C: Platelets
21 CFR 640.25 - General requirements.
21 CFR 640.25(a) - (a) Storage. Immediately after resuspension, Platelets shall be placed in storage at the selecte...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.25(b) - (b) Quality control testing
21 CFR 640.25(b) - (b) Quality control testing
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.25(b)(4) - (4) If the results of the quality control testing indicate that the product does not meet the pre...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.21 - Eligibility of donors.
21 CFR 640.21(e) - (e) Frequency of plateletpheresis collection.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.21(g) - (g) The responsible physician must obtain the informed consent of a plateletpheresis donor on the...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.21(f) - (f) Deferral of plateletpheresis donors due to red blood cell loss.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.21(a) - (a) Establishments must determine the eligibility of donors of platelets derived from Whole Blood...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.24 - Processing.
21 CFR 640.24(b) - (b) Immediately after collection, the whole blood or plasma shall be held in storage between 20 a...
Enforcement history
Companies cited for this
Warning Letters
Subpart D: Plasma
21 CFR 640.31 - Eligibility of donors.
21 CFR 640.31(b) - (b) Collection establishments must determine the eligibility of plasmapheresis donors in accordan...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.31 - Eligibility of donors.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.34 - Processing.
21 CFR 640.34(c) - (c) Liquid Plasma. Liquid Plasma shall be separated from the red blood cells and shall be stored...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.34(b) - (b) Fresh Frozen Plasma. Fresh frozen plasma shall be prepared from blood collected by a single ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.34(g) - (g) The final product.
21 CFR 640.34(g)(1) - (1) The final product shall be inspected immediately after separation of the plasma and shall not...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.34(g)(2) - (2) With the exception of Platelet Rich Plasma and Liquid Plasma the final product shall be inspe...
Enforcement history
Companies cited for this
Warning Letters
Subpart F: Cryoprecipitate
21 CFR 640.56 - Quality control test for potency.
21 CFR 640.56(d) - (d) If the average potency level of antihemophilic factor in the containers tested is less than 8...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.52 - Collection of source material.
Enforcement history
Companies cited for this
Warning Letters
Subpart G: Source Plasma
21 CFR 640.66 - Immunization of donors.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.73 - Reporting of fatal donor reactions.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65 - Plasmapheresis.
21 CFR 640.65(b) - (b) Procedures-specific requirements. The plasmapheresis procedure shall meet the following requ...
21 CFR 640.65(b)(3) - (3) A donor identification system shall be established that positively identifies each donor and ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65(b)(4) - (4) The amount of whole blood, not including anticoagulant, removed from a donor during a manual ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65(b)(8) - (8) The volume of plasma collected during an automated plasmapheresis collection procedure shall ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65(b)(1) - (1)
21 CFR 640.65(b)(1)(i) - (i) Except as provided under § 630.25 of this chapter, the responsible physician must draw a samp...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65(b)(1)(iii) - (iii) A repeat donor from whom the plasmapheresis center is unable to obtain a sample for testing...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.65(b)(2) - (2)
21 CFR 640.65(b)(2)(i) - (i) Except as provided under § 630.25 of this chapter, the responsible physician must review the ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.64 - Collection of blood for Source Plasma.
21 CFR 640.64(e) - (e) Prevention of contamination of the blood and plasma. The skin of the donor at the site of ph...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.69 - General requirements.
21 CFR 640.69(b) - (b) Storage. Immediately after filling, plasma intended for manufacturing into injectable produc...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72 - Records.
21 CFR 640.72(d) - (d) If a donor has a reaction while on the plasmapheresis premises, or a donor reaction is report...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72(b) - (b) Each donor record must be directly cross-referenced to the unit(s) of Source Plasma associate...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72(a) - (a) In addition to the recordkeeping requirements of this subchapter, the following records shall...
21 CFR 640.72(a)(1) - (1) Documentation shall be available to ensure that the shipping temperature requirements of § 60...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72(a)(2) - (2)
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72(a)(3) - (3) The original or a clear copy or other durable record which may be electronic of the donor's c...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.72(a)(4) - (4) Records of the medical history and physical examination of the donor conducted in accordance ...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.76 - Products stored or shipped at unacceptable temperatures.
21 CFR 640.76(c) - (c) Relabeling. If Source Plasma is required to be relabeled as “Source Plasma Salvaged” under p...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.76(a) - (a) Storage temperature.
21 CFR 640.76(a)(2) - (2) Source Plasma intended for manufacture into injectable products that is exposed inadvertently...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.68 - Processing.
21 CFR 640.68(b) - (b) Final containers. Final containers used for Source Plasma, whether integrally attached or se...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.67 - Laboratory tests.
Enforcement history
Companies cited for this
Warning Letters
Subpart H: Albumin (Human)
21 CFR 640.81 - Processing.
21 CFR 640.81(c) - (c) Microbial contamination. All processing steps shall be conducted in a manner to minimize the...
Enforcement history
Companies cited for this
Warning Letters
Subpart L: Alternative Procedures
21 CFR 640.120 - Alternative procedures.
21 CFR 640.120(a) - (a) The Director, Center for Biologics Evaluation and Research, may issue an exception or alterna...
Enforcement history
Companies cited for this
Warning Letters
21 CFR 640.120 - Alternative procedures.
Enforcement history
Companies cited for this
Warning Letters
Part 660: Additional Standards for Diagnostic Substances for Laboratory Tests
Subpart D: Reagent Red Blood Cells
21 CFR 660.32 - Collection of source material.
Enforcement history
Companies cited for this
Warning Letters
21 CFR 660.31 - Eligibility of donor.
Enforcement history
Companies cited for this
Warning Letters